Literature DB >> 12644005

Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.

P Jourdain1, F Funck, M Bellorini, N Guillard, J Loiret, B Thebault, M Desnos, D Duboc.   

Abstract

OBJECTIVES: To determine if B-type natriuretic peptide (BNP) measurement could be useful in determination of functional capacity in patients suffering from chronic heart failure.
BACKGROUND: Evaluating functional capacity is a crucial factor in the follow-up of patients with chronic heart failure. There are numerous methods for measuring functional capacity and their relative merits remain under discussion. Clinical classifications are very subjective and other methods are difficult to use in clinical practice.
METHODS: We evaluated functional capacity in 151 consecutive patients using the 6-min walk test. All patients were clinically classified using the New York Heart Association (NYHA) classification. We measured BNP plasma levels using a bedside BNP test.
RESULTS: Six minute walk test performance decreased through NYHA classes 1 to 4 (469+/-87, 411+/-82, 325+/-83 and 196+/-63 m, respectively, P<0.01) and BNP levels increased through NYHA classes 1 to 4 (26.3+/-7.2, 73+/-13, 401+/-74 and 924+/-84 pg/ml, respectively, P<0.001). There was a significant correlation between 6-min walk test performance and BNP plasma levels (R=0.69 P<0.001) and a weaker correlation between BNP and left ventricular ejection fraction (R=0.45 P<0.04). In some patients there was a mismatch between NYHA classification and 6-min walk test performance. In all cases BNP could correct the clinical estimation of functional capacity. When we divided the patients into three sub-groups within each NYHA class, we showed that using BNP could better define functional capacity in patients suffering from chronic heart failure in NYHA classes I to III.
CONCLUSION: The measurement of BNP levels thus usefully supplements the clinical examination. The existence of bedside BNP testing methods facilitates its use in routine clinical practice. It also permits easier follow-up of patients with chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644005     DOI: 10.1016/s1388-9842(02)00247-7

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  11 in total

1.  Evaluation of heart function with impedance cardiography in acute myocardial infarction patients.

Authors:  Shun-Juan Chen; Zhu Gong; Qiang-Lin Duan
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 2.  Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.

Authors:  J Malcom O Arnold; Jonathan G Howlett; Paul Dorian; Anique Ducharme; Nadia Giannetti; Haissam Haddad; George A Heckman; Andrew Ignaszewski; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; John D Parker; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Vivek Rao; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2007-01       Impact factor: 5.223

3.  Relationship of left atrial global peak systolic strain with left ventricular diastolic dysfunction and brain natriuretic peptide level in end-stage renal disease patients with preserved left ventricular ejection fraction.

Authors:  Leila Abid; Salma Charfeddine; Samir Kammoun
Journal:  J Echocardiogr       Date:  2016-02-09

Review 4.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

5.  N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study.

Authors:  G Michael Felker; David Whellan; William E Kraus; Robert Clare; Faiez Zannad; Mark Donahue; Kirkwood Adams; Robert McKelvie; Ileana L Piña; Christopher M O'Connor
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

6.  To Evaluate the Change in Brain Natriuretic Peptide Levels in Outpatients with Ischemic Cardiomyopathy and Its Association with Functional Capacity: A Pilot Study.

Authors:  Amarapalli Jayachandra; Vivek Aggarwal
Journal:  J Clin Diagn Res       Date:  2017-06-01

7.  Biomarkers in outpatient heart failure management; Are they correlated to and do they influence clinical judgment?

Authors:  J M P W U Peeters; S Sanders-van Wijk; S Bektas; C Knackstedt; P Rickenbacher; F Nietlispach; R Handschin; M T Maeder; S F Muzzarelli; M E Pfisterer; H P Brunner-La Rocca
Journal:  Neth Heart J       Date:  2014-03       Impact factor: 2.380

8.  Natriuretic Peptide testing in primary care.

Authors:  Shafiq U Rehman; James L Januzzi
Journal:  Curr Cardiol Rev       Date:  2008-11

9.  The biological variation of N-terminal pro-brain natriuretic peptide in postmenopausal women with type 2 diabetes: a case control study.

Authors:  Susana González; Eric S Kilpatrick; Stephen L Atkin
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

10.  The effects of super-flux (high performance) dialyzer on plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-Terminal proBNP in end-stage renal disease patients on dialysis.

Authors:  Yasuaki Nakagawa; Toshio Nishikimi; Koichiro Kuwahara; Shinji Yasuno; Hideyuki Kinoshita; Yoshihiro Kuwabara; Kazuhiro Nakao; Takeya Minami; Chinatsu Yamada; Kenji Ueshima; Yoshihiro Ikeda; Hiroyuki Okamoto; Kazukiyo Horii; Kiyoshi Nagata; Kenji Kangawa; Naoto Minamino; Kazuwa Nakao
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.